Literature DB >> 22977550

Bronchial reversibility with a short-acting β2-agonist predicts the FEV1 response to administration of a long-acting β2-agonist with inhaled corticosteroids in patients with bronchial asthma.

Akihiko Ohwada1, Kei Inami, Emi Onuma, Mariko Matsumoto-Yamazaki, Ryo Atsuta, Kazuhisa Takahashi.   

Abstract

A long-acting β2-agonist (LABA) combined with an inhaled corticosteroid (ICS) is frequently prescribed as initial therapy in steroid-naïve asthma patients because of its effective control of symptoms and improvement of pulmonary function. However, it is unclear which patients will be responsive to LABAs and whether bronchial responsiveness to LABAs is similar to that to short-acting β2-agonists (SABAs) in a clinical setting. Therefore, the goal of the present study was to compare the changes in spirometric parameters after SABA (salbutamol) inhalation to those after 1-month LABA/ICS (salmeterol/fluticasone propionate) therapy. Spirometric changes were evaluated as absolute values, as the percentage of predicted normal values and as the percentage of baseline values after salbutamol inhalation or 1-month LABA/ICS therapy in 45 patients with asthma. Compared to SABA inhalation, LABA/ICS therapy produced significant improvements in forced expiratory volume in 1 sec (FEV1), peak expiratory flow (PEF), forced expiratory flow at 50% of vital capacity expired (FEF50%) from baseline (expressed as the percentage predicted) in all patients. FEV1 and the FEV1/forced vital capacity (FVC) ratio after SABA or LABA/ICS therapy were inversely related to the corresponding baseline values. Analysis of spirometric changes after SABA inhalation showed that FEV1 was the best among spirometric parameters, such as PEF, correlated with responsiveness to LABA/ICS therapy. Reversibility of FEV1 with SABA inhalation predicts the spirometric response to LABA/ICS as initial therapy in patients with bronchial asthma. LABA/ICS therapy had a greater effect on bronchial reversibility in asthmatic patients, compared to SABA inhalation. This suggested that evaluation of bronchial reversibility after LABA/ICS therapy would be superior to that after SABA inhalation.

Entities:  

Year:  2011        PMID: 22977550      PMCID: PMC3440754          DOI: 10.3892/etm.2011.268

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  11 in total

1.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

2.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

3.  Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1991-11

4.  The FDA and safe use of long-acting beta-agonists in the treatment of asthma.

Authors:  Badrul A Chowdhury; Gerald Dal Pan
Journal:  N Engl J Med       Date:  2010-02-24       Impact factor: 91.245

5.  Peripheral inflammation in patients with asthmatic symptoms but normal lung function.

Authors:  Lauri Lehtimäki; Hannu Kankaanranta; Seppo Saarelainen; Väinö Turjanmaa; Eeva Moilanen
Journal:  J Asthma       Date:  2005-09       Impact factor: 2.515

6.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.

Authors:  Harold S Nelson; Scott T Weiss; Eugene R Bleecker; Steven W Yancey; Paul M Dorinsky
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

7.  Retrospective characterization of airway reversibility in patients with asthma responsive to bronchodilators.

Authors:  Steven W Yancey; Hector G Ortega
Journal:  Curr Med Res Opin       Date:  2007-12       Impact factor: 2.580

8.  Asthma mortality and long-acting beta2-agonists in five major European countries, 1994-2004.

Authors:  Liliane Chatenoud; Matteo Malvezzi; Andrea Pitrelli; Carlo La Vecchia; Francesco Bamfi
Journal:  J Asthma       Date:  2009-08       Impact factor: 2.515

Review 9.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

10.  Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group.

Authors:  P L Brand; P H Quanjer; D S Postma; H A Kerstjens; G H Koëter; P N Dekhuijzen; H J Sluiter
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

View more
  3 in total

1.  Heterogeneity of perception of symptoms in patients with asthma.

Authors:  Akihiko Ohwada; Katsuhiko Sato
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Small Airways Response to Bronchodilators in Adults with Asthma or COPD: A Systematic Review.

Authors:  Mohammed A Almeshari; Nowaf Y Alobaidi; Elizabeth Sapey; Omar Usmani; Robert A Stockley; James A Stockley
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-11

3.  Concave pattern of a maximal expiratory flow-volume curve: a sign of airflow limitation in adult bronchial asthma.

Authors:  Akihiko Ohwada; Kazuhisa Takahashi
Journal:  Pulm Med       Date:  2012-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.